Research
Metabolic adaptation
Tirzepatide treatment was associated with greater decreases in glycated hemoglobin and body weight compared to GLP-1 RA.
Practitioners can expect tirzepatide to be more effective in managing blood sugar and weight in patients with type 2 diabetes.
StrongSupportsmedium confidence
Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, -0.34 percentage points) and body weight (treatment difference, -2.9 kg) compared with GLP-1 RA.
Why this rating
Based on a large retrospective cohort study design.
Source
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang et al. · JAMA Network Open · 2024
cohort · n=140308Cited 106×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →